IL-6 is known to be significantly produced by BC cellsand cancer-associated adipocytes (CAAs), with the potential of inducing proliferation, EMT, stem cell phenotype, angiogenesis, cachexia, and therapeutic resistance in BC cells [131], correlating with clinical disease stage and lymph node metastasis as well as with ER and HER2 expression [132]. Here, ESR1 is linked to breast cancer.